Exploring Three High Growth Tech Stocks In The United States

In This Article:

Over the last 7 days, the United States market has experienced a 3.5% drop, yet it has shown resilience with a 22% rise over the past year and an anticipated annual earnings growth of 15%. In this dynamic environment, identifying high-growth tech stocks involves assessing their potential to capitalize on technological advancements and market trends while aligning with robust growth forecasts.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

23.95%

24.32%

★★★★★★

Ardelyx

25.47%

69.63%

★★★★★★

Sarepta Therapeutics

23.98%

42.48%

★★★★★★

Alnylam Pharmaceuticals

22.34%

70.30%

★★★★★★

Clene

77.61%

59.19%

★★★★★★

TG Therapeutics

34.86%

56.98%

★★★★★★

Alkami Technology

21.99%

102.65%

★★★★★★

Travere Therapeutics

31.70%

72.51%

★★★★★★

Seagen

22.57%

71.80%

★★★★★★

ImmunoGen

26.00%

45.85%

★★★★★★

Click here to see the full list of 237 stocks from our US High Growth Tech and AI Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

aTyr Pharma

Simply Wall St Growth Rating: ★★★★★☆

Overview: aTyr Pharma, Inc. is a biotherapeutics company focused on discovering and developing medicines targeting novel immunological pathways in the United States, with a market capitalization of $264.42 million.

Operations: The company generates revenue primarily from its biotechnology segment, specifically in startups, amounting to $0.24 million.

aTyr Pharma, despite its modest revenue of $235K, is navigating a high-growth trajectory with an anticipated revenue increase of 80.2% annually. This growth is significantly above the U.S. market average of 9.1%. The company's recent strategic board appointment and ongoing Phase 3 trials for efzofitimod highlight its commitment to innovation in treating inflammatory lung diseases, a market with few effective treatments. However, financial challenges persist as evidenced by an increased net loss to $49.06 million from last year's $35.63 million, underscoring the risks involved in its high-stakes biotech sector.

NasdaqCM:ATYR Revenue and Expenses Breakdown as at Dec 2024
NasdaqCM:ATYR Revenue and Expenses Breakdown as at Dec 2024

Vanda Pharmaceuticals

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapies for high unmet medical needs globally, with a market capitalization of approximately $265.30 million.

Operations: Vanda Pharmaceuticals generates revenue primarily from its biotechnology segment, amounting to $190.86 million. The company's focus is on developing and commercializing therapies for unmet medical needs globally.